University of Pennsylvania Philadelphia, Pennsylvania
Director, Abramson Cancer Center John H. Glick, MD Abramson Cancer Center’s Professor Vice Dean, Cancer Programs, Perelman School of Medicine Vice President, Cancer Programs, University of Pennsylvania Health System University of Pennsylvania Philadelphia, Pennsylvania
Developing new immune therapies, including vaccines, for breast cancer patients.
Re-igniting our immune systems to fight off cancer is one of the most promising new pathways for cancer therapy. The initial boom of drugs in this field, “immunotherapies,” produced exciting results in melanoma and lung cancer, but to date have limited impact in breast cancer. Scientists are only beginning to scratch the surface of their potential and have much more to understand about how to make them work effectively in all patients. Dr. Vonderheide and his team are working to not only improve currently available immunotherapies, but also develop new drugs that enhance the immune system in breast cancer patients.
Recent successes in early-stage vaccine trials from Dr. Vonderheide and his team led to an exciting new trial in breast cancer for individuals with BRCA1 and BRCA2 mutations, which is now open and accruing patients. The trial has two patient cohorts: patients with BRCA-associated breast cancer, and individuals without cancer who also carry a mutation in BRCA. This will be the first prevention vaccine ever tested in this high-risk population.
In the coming year, Dr. Vonderheide’s team will complete enrollment in the vaccine trial for healthy individuals who carry mutations in BRCA1 and BRCA2. He and his team will perform necessary review of adverse events and assess safety and whether to proceed with the next cohorts of participants. If successful, Dr. Vonderheide will then design a large-scale clinical trial of DNA vaccine immunoprevention in BRCA1 and BRCA2 carriers. He also plans to re-examine early events in breast cancer formation using a novel breast cancer model and explore other DNA vaccine prototypes preclinically.
Robert H. Vonderheide, MD, DPhil, is the Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center’s Director Professor in the Perelman School of Medicine. He is Vice Dean for Cancer Programs at PSOM and Vice President of Cancer Programs for the University of Pennsylvania Health System. He serves as Lead Physician for the Cancer Service Line of the Health System.
Dr. Vonderheide graduated from the University of Notre Dame (Chemical Engineering) and obtained his DPhil in immunology from Oxford University as a Rhodes Scholar. He graduated from Harvard Medical School and completed a residency in Internal Medicine at the Massachusetts General and a fellowship in medical oncology at the Dana Farber. As an NIH-funded investigator at Penn Medicine, Dr. Vonderheide directs a research team focused on cancer immunology and immunotherapy. He has published more than 160 peer-reviewed manuscripts with senior-author papers in high-impact journals such as Science, Nature, Cancer Cell, and the New England Journal of Medicine. He is well-known for deciphering the immune mechanisms of CD40 activation in cancer and directing clinical trials of novel immunotherapy.
Nationally, Dr. Vonderheide is a member of the National Cancer Institute Board of Scientific Advisers, the National Comprehensive Cancer Network Board of Directors, and serves as Deputy Editor of Cancer Immunology Research. He is an elected member of the American Society of Clinical Investigation (serving on the ASCI council from 2014-2017) and American Association of Physicians.
2007
The Leonard and Judy Lauder Fund Award
Please remember BCRF in your will planning. Learn More
